Financings Material −

Perimeter Medical Imaging AI Announces LIFE Financing and Concurrent Private Placement

Perimeter Medical Imaging AI Secures Lifeline Financing at Discount to Market Price Amidst Cash Burn Concerns

By The Northwire Desk — AI Analysis Apr 21, 2026 · 07:15 PINK · 0.415 Perimeter Medical Imaging AI, Inc.

Executive Summary

Financing Announcement: On April 21, 2026, Perimeter announced a Listed Issuer Financing Exemption (LIFE) offering of up to $7.52 million CAD at $0.35 per unit and a concurrent private placement of convertible debentures for up to $5 million USD.
Unit Structure: LIFE units consist of one common share and one warrant exercisable at $0.50 CAD for 60 months. Debenture units include shares and warrants exercisable at $0.59 per share.
Insider Participation: CEO Adrian Mendes and SC Master Holdings LLC (Social Capital) have binding agreements to subscribe for approximately $5.5 million USD in total proceeds across both offerings.
Redomiciling: The company is evaluating a jurisdictional move from British Columbia, Canada, to the United States.
Closing Dates: Debentures expected to close April 24, 2026; LIFE offering expected May 5, 2026.
Use of Proceeds: Working capital and general corporate purposes, specifically supporting the commercial launch of the FDA-approved Claire™ device.

Material Impact

Dilution at Discount: The LIFE offering price of $0.35 CAD represents a discount of approximately 17% to the recent market price of $0.42 CAD (as of April 20, 2026). This is value-destructive for existing shareholders and signals management's urgency to secure liquidity over share price preservation.
Cash Runway Stress: As of December 31, 2025, the company held ~$2.5 million USD in cash. With Q4 2025 operating expenses at $2.5 million USD, the burn rate suggests a runway of less than six months without this financing. The April timing confirms liquidity stress is imminent.
Positive Counterbalance: The participation of CEO Adrian Mendes and SC Master Holdings (Social Capital) provides some validation of the company's direction, preventing a total collapse in confidence. However, their investment does not offset the dilution impact on public float holders.
Redomiciling Risk: Moving jurisdiction to the U.S. introduces regulatory complexity and potential tax implications that may distract management from commercial execution during the critical Claire™ launch phase.

PINK · Price

Company Overview

Company Profile: Perimeter Medical Imaging AI develops intra-operative imaging systems using Optical Coherence Tomography (OCT) combined with Artificial Intelligence to assess surgical margins in real-time.
Flagship Project: Claire™ is the first FDA PMA-approved AI-enabled intra-operative breast cancer margin assessment device (approved March 2026). It aims to reduce repeat surgeries by providing immediate tissue analysis during surgery.
Secondary Product: S-Series OCT system (FDA 510(k) cleared), currently generating revenue through leases and consumables at hospitals like HCA HealthONE Rose and Intermountain Health.
Development Stage: Transitioning from clinical development to commercialization. Revenue grew 172% YoY in FY2025, but the company remains unprofitable with a net loss of $12.9 million for the year.

More from Perimeter Medical Imaging AI, Inc.